June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Valproic acid reduces resident neuroinflammation and provides neuroprotection following retinal ganglion cell axotomy
Author Affiliations & Notes
  • James R Tribble
    Clinical Neuroscience, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Elizabeth Kastanaki
    Clinical Neuroscience, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • A. Bersan Uslular
    Clinical Neuroscience, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Carola Rutigliani
    Clinical Neuroscience, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Tim J Enz
    Clinical Neuroscience, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Pete A Williams
    Clinical Neuroscience, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Footnotes
    Commercial Relationships   James Tribble None; Elizabeth Kastanaki None; A. Bersan Uslular None; Carola Rutigliani None; Tim Enz None; Pete Williams None
  • Footnotes
    Support  Karolinska Institut Foundation Grants for Eye Research FS-2020:0009
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1613 – A0436. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      James R Tribble, Elizabeth Kastanaki, A. Bersan Uslular, Carola Rutigliani, Tim J Enz, Pete A Williams; Valproic acid reduces resident neuroinflammation and provides neuroprotection following retinal ganglion cell axotomy. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1613 – A0436.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Neuroinflammation is an early and persistent feature of retinal pathophysiology. Understanding the interaction of retinal neurons and resident glia cells (microglia, astrocytes, and Müller glia) is important for identifying disease mechanisms and drug targets. Attributing neuroinflammatory events to resident or infiltrating immune cells is non-trivial since simple tools and models to separate these do not exist. Using a retinal explant model, where axotomy and maintenance of the retina ex vivo drives rapid retinal ganglion cell neurodegeneration, we assessed resident neuroinflammation

Methods : Retina from C57BL/6J mice were dissected and maintained as retinal explants for 0 (control) or 24 hrs. LPS (100 ng / mL) or Valproic acid (1 mM) were dissolved in the culture media. Retinal neuroinflammation was quantified by morphological and protein analysis. Fixed retinas were immunofluorescently labeled for RBPMS (retinal ganglion cells), IBA1 (microglia), and GFAP (astrocytes), imaged on a confocal microscope, and 3D morphology reconstructed using Imaris. Dissociated retinas were assessed for cytokine and chemokine expression by protein array (109 proteins)

Results : Twenty-four hours after axotomy, retinas displayed significantly altered microglia and astrocyte morphologies. The morphology of microglia processes was, on average, more contracted and voluminous, consistent with a shift towards inflammatory phenotypes. Astrocyte networks increased in filament density and connectivity. Key inflammatory cytokines were significantly upregulated (Ccl5, Cxcl10, Ccl2, Il-1α, Cxcl1, Icam-1). This is consistent with in vivo retinal ganglion cell injury. As a putative positive control, LPS (a known inflammatory activator), further retracted microglial morphology and further increased Ccl5, Cxcl10, and Il-12, but did not affect astrocyte morphology. Valproic acid provided neuroprotection, significantly reduced morphological changes of both microglia and astrocytes, and maintained Ccl5, Cxcl10, Ccl22, Il-12, Ccl2, and Cxcl1 at uninjured control levels

Conclusions : We demonstrate that the retinal explant model allows for the isolated study of resident glial neuroinflammation without the influence of the circulatory system. This model allows for rapid testing of compounds which may modify neuroinflammation and identifies Valproic acid as a drug which limits retinal neuroinflammation

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×